APEPTICO is developing a portfolio of peptide-based products based on its PEPBASE™ discovery technology.

APEPTICO’s lead molecule, AP301, is a synthetic peptide that corresponds to a structural motif of the human Tumour Necrosis Factor alpha. AP301 activates lung fluid clearance and protects both endothelial and epithelial lung tissue from microbial toxin- and reactive oxygen species-induced hyper-permeability. It is being developed by APEPTICO in various pulmonary indications.
AP301-IH has been designed for the treatment of Pulmonary Oedema in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). ALI and ARDS are life-threatening diseases associated with a mortality rate of 30% to 60%. Currently, no specific treatment is available.
AP301-IRI has being developed for the prevention and treatment of Ischemia Reperfusion Injury during lung transplantation. Ischemia Reperfusion Injury is a major cause for primary graft failure.
AP301-PN is being developed for the prevention and treatment of hyper-permeability upon microbial and/or viral infection of the lower respiratory tract. Even if lung tissue is sterile due antibiotic treatment, microbial toxins and viral proteins may cause hyper-permeability thus disrupting the endothelial-epithelial barrier function.

AP301 has received Orphan Drug Designation for the treatment of Acute Lung Injury.

Tel +43 (0)664 1432919  |  Mail office@apeptico.com